Literature DB >> 34607633

Association of Proton Pump Inhibitors With Higher Risk of Cardiovascular Disease and Heart Failure.

Elizabeth J Bell1, Suzette J Bielinski2, Jennifer L St Sauver2, Lin Y Chen3, Mary R Rooney4, Nicholas B Larson5, Paul Y Takahashi6, Aaron R Folsom7.   

Abstract

OBJECTIVE: To examine associations of cumulative exposure to proton pump inhibitors (PPIs) with total cardiovascular disease (CVD; composed of stroke, coronary heart disease, and heart failure [HF]) and HF alone in a cohort study of White and African American participants of the Atherosclerosis Risk in Communities (ARIC) study.
METHODS: Use of PPIs was assessed by pill bottle inspection at visit 1 (January 1, 1987 to 1989) and up to 10 additional times before baseline (visit 5; 2011 to 2013). We calculated cumulative exposure to PPIs as days of use from visit 1 to baseline. Participants (n=4346 free of total CVD at visit 5; mean age, 75 years) were observed for incident total CVD and HF events through December 31, 2016. We used Cox regression to measure associations of PPIs with total CVD and HF.
RESULTS: After adjustment for potential confounding variables, participants with a cumulative exposure to PPIs of more than 5.1 years had a 2.02-fold higher risk of total CVD (95% CI, 1.50 to 2.72) and a 2.21-fold higher risk of HF (95% CI, 1.51 to 3.23) than nonusers.
CONCLUSION: Long-term PPI use was associated with twice the risk of total CVD and HF compared with nonusers. Our findings are in concordance with other research and suggest another reason to be cautious of PPI overuse.
Copyright © 2021 Mayo Foundation for Medical Education and Research. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34607633      PMCID: PMC8631442          DOI: 10.1016/j.mayocp.2021.02.025

Source DB:  PubMed          Journal:  Mayo Clin Proc        ISSN: 0025-6196            Impact factor:   11.104


  36 in total

1.  An evaluation of the use of proton pump inhibitors.

Authors:  N M Walker; J McDonald
Journal:  Pharm World Sci       Date:  2001-06

2.  Classification of heart failure in the atherosclerosis risk in communities (ARIC) study: a comparison of diagnostic criteria.

Authors:  Wayne D Rosamond; Patricia P Chang; Chris Baggett; Anna Johnson; Alain G Bertoni; Eyal Shahar; Anita Deswal; Gerardo Heiss; Lloyd E Chambless
Journal:  Circ Heart Fail       Date:  2012-01-23       Impact factor: 8.790

3.  Increased use of acid-suppressing drugs before the occurrence of ischemic events: a potential source of confounding in recent observational studies.

Authors:  David F Blackburn; Darcy A Lamb; Melanie M Mcleod; Dean T Eurich
Journal:  Pharmacotherapy       Date:  2010-10       Impact factor: 4.705

4.  Acid suppressive therapy use on an inpatient internal medicine service.

Authors:  Co Q D Pham; Randolph E Regal; Thomas R Bostwick; Kara S Knauf
Journal:  Ann Pharmacother       Date:  2006-06-27       Impact factor: 3.154

5.  Systematic review with meta-analysis: risk of adverse cardiovascular events with proton pump inhibitors independent of clopidogrel.

Authors:  Riley Batchelor; Radya Kumar; Julia F M Gilmartin-Thomas; Ingrid Hopper; William Kemp; Danny Liew
Journal:  Aliment Pharmacol Ther       Date:  2018-09-04       Impact factor: 8.171

6.  Heart failure incidence and survival (from the Atherosclerosis Risk in Communities study).

Authors:  Laura R Loehr; Wayne D Rosamond; Patricia P Chang; Aaron R Folsom; Lloyd E Chambless
Journal:  Am J Cardiol       Date:  2008-02-14       Impact factor: 2.778

7.  Serum magnesium, phosphorus, and calcium are associated with risk of incident heart failure: the Atherosclerosis Risk in Communities (ARIC) Study.

Authors:  Pamela L Lutsey; Alvaro Alonso; Erin D Michos; Laura R Loehr; Brad C Astor; Josef Coresh; Aaron R Folsom
Journal:  Am J Clin Nutr       Date:  2014-07-16       Impact factor: 7.045

8.  Severe hypomagnesaemia in long-term users of proton-pump inhibitors.

Authors:  T Cundy; A Dissanayake
Journal:  Clin Endocrinol (Oxf)       Date:  2008-01-23       Impact factor: 3.478

9.  Dietary and plasma magnesium and risk of coronary heart disease among women.

Authors:  Stephanie E Chiuve; Qi Sun; Gary C Curhan; Eric N Taylor; Donna Spiegelman; Walter C Willett; Joann E Manson; Kathryn M Rexrode; Christine M Albert
Journal:  J Am Heart Assoc       Date:  2013-03-18       Impact factor: 5.501

10.  Omeprazole impairs vascular redox biology and causes xanthine oxidoreductase-mediated endothelial dysfunction.

Authors:  Lucas C Pinheiro; Gustavo H Oliveira-Paula; Rafael L Portella; Danielle A Guimarães; Celio D de Angelis; Jose E Tanus-Santos
Journal:  Redox Biol       Date:  2016-08-04       Impact factor: 11.799

View more
  2 in total

Review 1.  Modification of Cardiovascular Drugs in Advanced Heart Failure: A Narrative Review.

Authors:  Manuel Martínez-Sellés; Tomasz Grodzicki
Journal:  Front Cardiovasc Med       Date:  2022-05-23

2.  Association between Benign Paroxysmal Positional Vertigo and Previous Proton Pump Inhibitor Use: A Nested Case-Control Study Using a National Health Screening Cohort.

Authors:  So Young Kim; Dae Myoung Yoo; Mi Jung Kwon; Ji Hee Kim; Joo-Hee Kim; Joong Seob Lee; Hyo Geun Choi
Journal:  Int J Environ Res Public Health       Date:  2022-08-18       Impact factor: 4.614

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.